7 completed, 1 active not recruiting. 4 Phase 1, 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow Medicare Part B: new trials by email Literature Review of Medicare Part B trials Research Report on Medicare Part B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral CDX-7108 in Healthy Adults and EPI Subjects Part A, Part B, Part C - Exocrine Pancreatic Insufficiency | Phase 1 | Completed | Société des Produits Nestlé (SPN) | 54 | 2021-10-11 | 2024-09-20 |
| Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL Zanubrutinib and Rituximab, R-DHAOx, Zanubrutinib Maintenance - Mantle Cell Lymphoma, Newly-diagnosed Mantle Cell Lymphoma | Phase 2 | Active not recruiting | Sun Yat-sen University | 42 | 2020-12-01 | 2024-10-18 |
| Surufatinib DDI With a PPI and a CYP3A Inducer Part A, Part B - Healthy | Phase 1 | Completed | Hutchison Medipharma Limited | 28 | 2020-07-09 | 2021-06-18 |
| A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease Part A: RPL554, Placebos, Part B: RPL554 - COPD | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 40 | 2019-04-29 | 2022-09-21 |
| Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies Part A, Part B - Advanced Malignancies | Phase 1 | Completed | TopAlliance Biosciences | 184 | 2018-02-21 | 2024-11-22 |
| Effects of an 8-day Advanced Meditation, Samyama on Physical, Psychological and Spiritual Wellbeing ,and Associated Neural Mechanisms Part A1: Survey, Part A2: Sample collection, Part B: - Mental Health Wellness 1, Happiness | Not applicable | Completed | Indiana University | 759 | 2018-01-19 | 2024-10-03 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914 Part A, Part B - Gonococcal (GC) Infection | Phase 1 | Completed | AstraZeneca | 100 | 2013-09-01 | 2014-04-15 |
| HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II Part A, Part B - Arthritis, Rheumatoid | Phase 2 | Completed | GlaxoSmithKline | 201 | 2005-02-01 | 2012-11-12 |
Arthritis, Rheumatoid (1) · Carcinoma, Hepatocellular (1) · Chondrosarcoma (1) · Consciousness Disorders (1) · Depression (1) · Esophageal Neoplasms (1) · Exocrine Pancreatic Insufficiency (1) · Feeding Behavior (1) · Gonorrhea (1) · Infections (1) · Inflammatory Bowel Diseases (1) · Lymphoma, Mantle-Cell (1) · Nasopharyngeal Carcinoma (1) · Pulmonary Disease, Chronic Obstructive (1) · Sarcoma (1)
AstraZeneca (1) · GlaxoSmithKline (1) · Hutchison Medipharma Limited (1) · Indiana University (1) · Société des Produits Nestlé (SPN) (1) · Sun Yat-sen University (1) · TopAlliance Biosciences (1) · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (1)
United States (4) · Australia (1) · China (1) · New Zealand (1) · United Kingdom (1)
Chris Wynne (1) · David Mathews, MD (1) · Humphrey Gardener, MD (1) · John Windsor (1) · Nam Nguyen (1) · Qingqing Cai, MD (1) · Richard Stubbs (1) · Senthilkumar Sadhasivam, MD (1) · Sheng Yao, PhD (1) · Youngiun Kim, MD (1)
PMID 20506254, PMID 24443277, PMID 30373802, PMID 34867626, PMID 35532984, PMID 37020274, PMID 39816916